✨ Your Portfolio is fetched and updated from zerodha.

Senores Pharmaceuticals Ltd.

SENORES

Market Cap
₹2,601 Cr.
P/E
82.69

Senores Pharmaceuticals Ltd.

About
Senores Pharmaceuticals is a global research-driven company specializing in developing and manufacturing a wide range of generic pharmaceutical products for the B2B segment. They focus on regulated ma… Read more
Senores Pharmaceuticals is a global research-driven company specializing in developing and man… Read more
Low
440
52W Range
High
644
  • Senores Pharmaceutic
  • Ajanta Pharma
  • Alembic Pharma

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Company Timeline

Subscribe now for more updates
Custom financial statementNew
Edit rows
Forensics

8 Yes

Positive for this company

1 Neutral

Neutral for this company

4 No

Negative for this company

4 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operational Metrics

    locked
    Select a Metric
    • Number of ANDA's Filed in USA (.)
      Source
    • Number of ANDA's Approved By USFDA (.)
      Source
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    FAQs on Senores Pharmaceuticals Ltd. Business

    Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.

    Senores Pharmaceutic major competitors are Ajanta Pharma, Alembic Pharma, Caplin Point Lab, Gland Pharma, Strides Pharma Scien, Guj. Themis Biosyn, Suven Life Sciences.
    Market Cap of Senores Pharmaceutic is ₹2,654 Crs.
    While the median market cap of its peers are ₹14,110 Crs.

    Senores Pharmaceutic seems to be less financially stable compared to its competitors.
    Altman Z score of Senores Pharmaceutic is 4.8 and is ranked 7 out of its 8 competitors.

    View FAQ's On Shareprice
    Company Filing
    2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
    Annual Report FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
    Earnings Release Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Investor Presentation Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call Mar Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Conference Call SummaryCon Call Summary Mar Mar Jun Sep Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
    Discussions & Analysis
    Ideas Dashboard
    Timeline
    Watchlist
    Portfolio
    Alerts
    Research
    Stock Screener
    Market
    Raw Material